Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Blarcamesine - Anavex Life Sciences

Drug Profile

Blarcamesine - Anavex Life Sciences

Alternative Names: AE-37 hydrochloride; ANA001-HCl; ANAVEX; ANAVEX 2-73; Blarcamesine hydrochloride

Latest Information Update: 14 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anavex Life Sciences
  • Developer Anavex Life Sciences; The Michael J. Fox Foundation for Parkinsons Research
  • Class Antidementias; Antidepressants; Antiepileptic drugs; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Furans; Neuroprotectants; Neuropsychotherapeutics; Nootropics; Small molecules
  • Mechanism of Action Muscarinic receptor modulators; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epilepsy; Fragile X syndrome; Rett syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Alzheimer's disease
  • Phase III Parkinson's disease
  • Phase II/III Fragile X syndrome; Rett syndrome; Unspecified
  • No development reported Angelman syndrome; Epilepsy

Most Recent Events

  • 07 Feb 2024 Anavex Life Sciences plans a phase II trial for Schizophrenia in Q2 2024 (PO)
  • 08 Jan 2024 Anavex Life Sciences has patent protection for Blarcamesine in Neurologic indications in USA
  • 02 Jan 2024 Efficacy and adverse events data from a phase II/III trial in Rett Syndrome released by Anavex Life Sciences
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top